ABVC BioPharma, Inc.
ABVC · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $796 | $0 | $0 | $2 |
| % Growth | – | – | -100% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $796 | $0 | $0 | $2 |
| % Margin | 100% | – | – | 100% |
| R&D Expenses | $30 | $33 | $29 | $32 |
| G&A Expenses | $0 | $2,262 | $664 | $304 |
| SG&A Expenses | $1,934 | $2,262 | $664 | $304 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $1,964 | $2,295 | $693 | $336 |
| Operating Income | -$1,168 | -$2,295 | -$693 | -$334 |
| % Margin | -146.8% | – | – | -16,996.8% |
| Other Income/Exp. Net | -$119 | -$14 | -$251 | $463 |
| Pre-Tax Income | -$1,287 | -$2,309 | -$944 | $129 |
| Tax Expense | $1 | $24 | $0 | $0 |
| Net Income | -$1,247 | -$2,257 | -$842 | $229 |
| % Margin | -156.6% | – | – | 11,663.5% |
| EPS | -0.054 | -0.13 | -0.06 | 0.017 |
| % Growth | 58.8% | -116.7% | -448.8% | – |
| EPS Diluted | -0.054 | -0.13 | -0.06 | 0.017 |
| Weighted Avg Shares Out | 23,257 | 17,387 | 14,968 | 13,321 |
| Weighted Avg Shares Out Dil | 23,257 | 17,387 | 14,968 | 13,321 |
| Supplemental Information | – | – | – | – |
| Interest Income | $16 | $19 | $19 | $12 |
| Interest Expense | $0 | $129 | $223 | $0 |
| Depreciation & Amortization | $6 | $81 | $114 | $179 |
| EBITDA | -$1,281 | -$2,099 | -$607 | -$30 |
| % Margin | -161% | – | – | -1,530.5% |